[1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors

US11261184B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Harald Engelhardt · Ebreichsdorf, AT
• Heribert Arnhof · Wien, AT
• Sebastian CAROTTA · Wien, AT
• Marco Hofmann · Wien, AT
• Marc Kerenyi · Wien, AT
• Dirk Scharn · Wien, AT

Key dates

• Filing date: Oct 1, 2018
• Grant date: Mar 1, 2022
• Expiry date: Nov 21, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K45/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention encompasses compounds of formula (I) wherein the groups R1 to R5, A and q have the meanings given in the claims and specification, their use as inhibitors of CDK8/19, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.